References
- 1Wadstrom BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023;44(16):1432–1445. DOI: 10.1093/eurheartj/ehac822
- 2Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study. Eur Heart J. 2021;42(42):4324–4332. DOI: 10.1093/eurheartj/ehab432
- 3Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138(8):770–781. DOI: 10.1161/CIRCULATIONAHA.117.032318
- 4Li J, Li Y, Zhu P, Xu J, Tang X, Qiao S, et al. Remnant cholesterol but not LDL cholesterol is associated with 5-year bleeding following percutaneous coronary intervention. iScience. 2023;26(10):107666. DOI: 10.1016/j.isci.2023.107666
- 5Wu Z, Zhang H, Xu Y, Li X, Li X, Balmer L, et al. Low remnant cholesterol and in-hospital bleeding risk after ischemic stroke or transient ischemic attack. J Am Heart Assoc. 2024;13(14):
e034307 . DOI: 10.1161/JAHA.124.034307 - 6Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550–559. DOI: 10.1002/ana.25432
- 7Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, et al. Oral antiplatelet therapy after acute coronary syndrome: A review. JAMA. 2021;325(15):1545–1455. DOI: 10.1001/jama.2021.0716
- 8Helten C, Naguib D, Dannenberg L, Pohl M, Ayhan A, Hohlfeld T, et al. Platelet function testing: Dead or alive. J Thromb Haemost. 2018;16(5):984–986. DOI: 10.1111/jth.13997
- 9Aradi D, Merkely B, Komocsi A. Platelet reactivity: Is there a role to switch? Prog Cardiovasc Dis. 2015;58(3):278–284. DOI: 10.1016/j.pcad.2015.08.008
- 10Iijima R, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. Ischemic and bleeding events in PENDULUM patients with high bleeding risk and high platelet reactivity. Circ J. 2022;86(5):763–771. DOI: 10.1253/circj.CJ-21-0717
- 11Goto S, Goto S. Statin treatment and the alterations in the platelet lipidome: What is the impact of lipid profile on thrombosis? Thromb Haemost. 2023;123(6):573–575. DOI: 10.1055/a-2052-9650
- 12Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–2273. DOI: 10.1016/j.jacc.2013.07.101
- 13Wisniewski A, Filipska K. The phenomenon of clopidogrel high on-treatment platelet reactivity in ischemic stroke subjects: A comprehensive review. Int J Mol Sci. 2020;21(17):6408. DOI: 10.3390/ijms21176408
- 14Castaner O, Pinto X, Subirana I, Amor AJ, Ros E, Hernaez A, et al. Remnant cholesterol, not ldl cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76(23):2712–2724. DOI: 10.1016/j.jacc.2020.10.008
- 15Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537–557. DOI: 10.1210/er.2018-00184
- 16Doi T, Langsted A, Nordestgaard BG. Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction. J Am Coll Cardiol. 2022;79(24):2383–2397. DOI: 10.1016/j.jacc.2022.03.384
- 17Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436. DOI: 10.1016/j.jacc.2012.08.1026
- 18Liao J, Qiu M, Su X, Qi Z, Xu Y, Liu H, et al. The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention. Lipids Health Dis. 2024;23(1):172. DOI: 10.1186/s12944-024-02156-3
- 19Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–635. DOI: 10.1016/S0140-6736(14)61177-6
- 20Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–563. DOI: 10.1161/CIRCRESAHA.115.306249
- 21Mochizuki M, Takada Y, Urano T, Nagai N, Nakano T, Nakajima K, et al. The in vitro effects of chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons. Thromb Res. 1996;81(5):583–593. DOI: 10.1016/0049-3848(96)00033-3
- 22Theofilis P, Sagris M, Antonopoulos AS, Oikonomou E, Tsioufis C, Tousoulis D. Inflammatory mediators of platelet activation: Focus on atherosclerosis and COVID-19. Int J Mol Sci. 2021;22(20):11170. DOI: 10.3390/ijms222011170
- 23Badimon L, Padro T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care. 2012;1(1):60–74. DOI: 10.1177/2048872612441582
- 24Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: An update. Eur Heart J. 2017;38(11):785–791. DOI: 10.1093/eurheartj/ehw550
- 25Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33(5):1294–304. DOI: 10.1016/S0735-1097(99)00018-2
- 26Grgurevich S, Krishnan R, White MM, Jennings LK. Role of in vitro cholesterol depletion in mediating human platelet aggregation. J Thromb Haemost. 2003;1(3):576–586. DOI: 10.1046/j.1538-7836.2003.00087.x